Online inquiry

IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15385MR)

This product GTTS-WQ15385MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD37 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001040031.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 951
UniProt ID P11049
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ15385MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14023MR IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA REGN-3500
GTTS-WQ1455MR IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ACD22-VCMMAE
GTTS-WQ7526MR IVTScrip™ mRNA-Anti-CLDN18, GC-182(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GC-182
GTTS-WQ6079MR IVTScrip™ mRNA-Anti-CCL2, CNTO 888(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CNTO 888
GTTS-WQ8150MR IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HL036337
GTTS-WQ10359MR IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY2062430
GTTS-WQ10939MR IVTScrip™ mRNA-Anti-HAVCR2, MBG-453(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MBG-453
GTTS-WQ11152MR IVTScrip™ mRNA-Anti-IFNAR1, MDX-1333(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MDX-1333
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW